The Down Under medical landscape is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for treating obesity. This treatment https://throbsocial.com/story23906537/retatrutide-australia-australia-a-new-prospect-for-obesity-treatment